You searched for Gout - Page 34 of 96

Abstract Number: 1115 • 2017 ACR/ARHP Annual Meeting
Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients
Fernando Perez-Ruiz¹ and Sandra Chinchilla², ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Barakaldo, Spain
Background/Purpose: adherence to urate-lowering treatment (ULT) in patients with gout is reported to be lower than 50% in the first year and below 20% at…
Abstract Number: 1116 • 2017 ACR/ARHP Annual Meeting
Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction
Dawen Zhang¹, Kichul Ko², Michael A. Becker² and Reem Jan¹, ¹Medicine, Rheumatology, University of Chicago, Chicago, IL, ²Medicine, University of Chicago, Chicago, IL
Background/Purpose: Patients with gout frequently have multiple serious co-morbidities, take concomitant medications, and have complex clinical profiles, making treatment of acute flares in hospital settings…
Abstract Number: 1117 • 2017 ACR/ARHP Annual Meeting
the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Martin Englund⁴, Nicola Dalbeth⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁵University of Auckland, Auckland, New Zealand, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Hyperuricemia i.e. increased s-uric acid levels (s-UA), is established risk factor for clinical gout. Studies regarding the absolute and relative effect on population level…
Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Douglas C.A. Taylor¹, An-Chen Fu¹ and Robert Morlock², ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 1123 • 2017 ACR/ARHP Annual Meeting
Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout
Sang Tae Choi¹, Seong-Jin Moon² and Eun-Jin Kang³, ¹Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ²Internal Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea, Republic of (South), ³Internal Medicine, Busan Medical Center, Busan, Korea, Republic of (South)
Background/Purpose: Gout is a chronic inflammatory disease resulted from hyperuricemia. The measurement of 24-hour urinary uric acid excretion is frequently used to evaluate disease status…
Abstract Number: 1125 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Acute Gouty Arthritis in Patients Hospitalized with Acute Coronary Syndromes and Congestive Heart Failure
Gabriela Montes-Rivera¹, Carla F Gamarra-Hilburn², Lorena González-Sepúlveda³ and Luis M. Vilá⁴, ¹Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁴Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hyperuricemia and untreated gout appears to be independent prognostic markers for poor all-cause and coronary heart disease mortality in patients with recent acute myocardial…
Abstract Number: 1127 • 2017 ACR/ARHP Annual Meeting
Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set
Amara Shaukat¹, Tim Jansen², M. Janssen³, Leo .A.B. Joosten⁴, Timothy Radstake⁵, Philip Riches⁶, Anne-Kathrin Tausche⁷, Jennie Harre Hindmarsh⁸, Nicola Dalbeth⁹, Lisa K. Stamp¹⁰ and Tony R. Merriman¹¹, ¹Univ Otago, Dunedin, New Zealand, ²VieCuri Medical Center, Venlo, Netherlands, ³Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ⁴Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶University of Edinburgh, Edinburgh, United Kingdom, ⁷Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁸Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁹University of Auckland, Auckland, New Zealand, ¹⁰University of Otago, Christchurch, New Zealand, ¹¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Gout results from formation of monosodium urate (MSU) crystals in the presence of hyperuricemia. Genome wide association studies have provided significant insights into hyperuricemia,…
Abstract Number: 1128 • 2017 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout
Wen-Ching Lan, Kuang-Hui Yu, Shue-Fen Luo, Chang-Fu Kuo and Tien-Ming Chan, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Appropriate dose of urate-lowering therapy (ULT) is needed for gout patients to dissolve existing urate crystals to prevent acute gout attacks and reduce the…
Abstract Number: 1129 • 2017 ACR/ARHP Annual Meeting
Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort
Laura Ranieri¹, Carolina Contero², Pedro Zapater^3,4 and Mariano Andrés^1,5, ¹Sección de Reumatología, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²Departamento de Medicina Clínica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ³Sección de Farmacología Clínica, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ⁴Departamento de Farmacología, Pediatría y Química Orgánica, UNIVERSIDAD MIGUEL HERNÁNDEZ, Alicante, Spain, ⁵Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Diuretics have been associated with impaired response to allopurinol and refractoriness in gout, but whether this stills after new urate-lowering treatments (ULT) and treat-to-target…
Abstract Number: 1130 • 2017 ACR/ARHP Annual Meeting
Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?
Sarah Keller¹, Sharan K. Rai², Na Lu¹, April Jorge³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Alcohol is a well-established risk factor for gout. However, more than 60 prospective studies have also shown that moderate alcohol intake is associated with…
Abstract Number: 1131 • 2017 ACR/ARHP Annual Meeting
The Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diets and Risk of Gout in Women: 28-Year Follow-up of a Prospective Cohort
Sarah Keller¹, Sharan K. Rai², Leo Lu³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: There is increasing recognition of a gout epidemic, exacerbated by an unhealthy diet and a sedentary lifestyle. Indeed, our recent study among men confirmed…
Abstract Number: 1133 • 2017 ACR/ARHP Annual Meeting
Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years
Sandra Chinchilla^1,2, Irati Urionagüena^2,3 and Fernando Perez-Ruiz^1,2,3, ¹University of the Basque Country (UPV/EHU), Bilbao, Spain, ²BioCruces Health Research Institute, Barakaldo, Spain, ³Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Gout is a rising cause of hospital admissions and emergency consults. It has even replaced rheumatoid arthritis as the principal rheumatological condition causing hospitalizations. Some…

Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients

Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction

the Absolute Risk of Clinically Diagnosed Gout By Serum Uric Acid Levels – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden

Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization

Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US

Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?

Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012

Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout

Factors Associated with Acute Gouty Arthritis in Patients Hospitalized with Acute Coronary Syndromes and Congestive Heart Failure

Replication of Genetic Association of Peroxisome Proliferator-Activated Receptor Gamma-1B with Gout in a New Zealand Polynesian Sample Set

Effect of Urate-Lowering Treatment on the Risk of Urolithiasis in People with Gout

Impact of Diuretics on Urate Lowering Therapy in Patients with Gout: Analysis of an Inception Cohort

Can Alcohol Intake in Moderation Lower the Risk of Myocardial Infarction and Mortality Even Among Gout Patients?

The Dietary Approaches to Stop Hypertension (DASH) and Mediterranean Diets and Risk of Gout in Women: 28-Year Follow-up of a Prospective Cohort

Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years

Simple Search Results